Janssen’s Tremfya wins psoriatic arthritis approval
The drug is the first IL-23 inhibitor approved for the condition
Read More
Tag: active psoriatic arthritis
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
